Clinical Research Directory

Inclusion Criteria: * Pathologically confirmed differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma; * Stage II-IVa (UICC 8th edition); * Acceptable induction chemotherapy and Tarceva targeted therapy; * No history of other malignant tumors; * Male or female, aged 65-80 years. * Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 times ULN; Alkaline phosphatase ≤ 5 times ULN; * Renal function: Creatinine clearance ≥ 60 ml/min or Creatinine ≤ 1.5 × ULN; * Hematological tests: Absolute Neutrophil Count (ANC) ≥ 2 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, and Hemoglobin ≥ 9 g/dL; * No severe dysfunction of vital organs such as heart and lung; * PS score ≤ 2 points Exclusion Criteria: * Distant metastases detected before treatment; * Refusal to sign the informed consent form; * Patients who cannot comply with regular follow-up due to psychological, social, family, or geographical reasons; * Simultaneously receiving other experimental treatments in clinical trials (during the treatment phase of clinical research); * Severe, uncontrolled infections or medical conditions; * Vital organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy and chemotherapy; * Laboratory tests: Total bilirubin \> Upper Limit of Normal (ULN); AST and/or ALT \> 1.5 times ULN with alkaline phosphatase \> 2.5 times ULN; * Factors affecting drug administration, distribution, metabolism, and excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.; * Long-term use of immunosuppressants after organ transplantation; * Patients with a history of other malignant tumors before enrollment.